Our EDMaRC researchers Anders Juul, Anna-Maria Andersson, and Niels Jrgensen have contributed to different chapters
If a patient opts to begin medication, it is essential to monitor and promptly address any emerging signs of exacerbation of eating disorder psychopathology (e.g., adoption of extreme and rigid dietary rules, skipping meals, self-inducing vomiting)
How do you sustain these transformative results long-term, particularly after discontinuing the medication
In September 2025, the two parties launched Zilebesiran's first phase IV clinical trial
It is important to remember that competition from new entrants can help drive down costs
However, this same mechanism can slow overall gastrointestinal transit time, potentially leading to constipation in some patients